Physiomics PLC - Oxfordshire, England-based mathematical modelling company that supports oncology drug development - Secures contract worth £102,000 with a new UK-based biotech firm that is focused on developing antibody drug conjugates based therapies targeting difficult-to-treat cancers. Says the contract will see it develop a pharmacokinetic pharmacodynamic model to inform optimal dosing for the client’s upcoming first-in-human trial. Expects the project to run from April until August this year. Chief Executive Peter Sargent says: ‘We are delighted to be awarded this contract. Not only is this contract with a brand new client, but is also in the area of ADCs; a hot new area of oncology treatments.’
Current stock price: 0.44 pence, up 1.4% on Monday afternoon in London.
12-month change: down 67%
Copyright 2025 Alliance News Ltd. All Rights Reserved.
